StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)

Close on Nov 17, 2026Market cap $1.78BP/E –Yield –

Agios Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Agios Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$360.60M. For fiscal 2025 it was -$372.98M. The highest annual figure on record is $38.56M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$372.98M–
FY2024Dec 31, 2024-$389.84M–
FY2023Dec 31, 2023-$296.06M–
FY2022Dec 31, 2022-$309.48M–
FY2021Dec 31, 2021-$407.32M–
FY2020Dec 31, 2020-$290.76M–
FY2019Dec 31, 2019-$370.62M–
FY2018Dec 31, 2018-$304.42M–
FY2017Dec 31, 2017-$285.23M-839.7%
FY2016Dec 31, 2016$38.56M–
FY2015Dec 31, 2015-$76.95M–
FY2014Dec 31, 2014-$59.35M–
FY2013Dec 31, 2013-$56.40M–
FY2012Dec 31, 2012-$49.55M–
FY2011Dec 31, 2011-$15.22M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$57.31M–
Q1 FY2026Mar 31, 2026-$118.92M–
Q4 FY2025Dec 31, 2025-$96.21M–
Q3 FY2025Sep 30, 2025-$88.15M–
Q2 FY2025Jun 30, 2025-$77.12M–
Q1 FY2025Mar 31, 2025-$111.49M–
Q4 FY2024Dec 31, 2024-$133.17M–
Q3 FY2024Sep 30, 2024-$84.22M–
Q2 FY2024Jun 30, 2024-$72.59M–
Q1 FY2024Mar 31, 2024-$99.87M–
Q4 FY2023Dec 31, 2023-$72.49M–
Q3 FY2023Sep 30, 2023-$61.64M–
Q2 FY2023Jun 30, 2023-$66.75M–
Q1 FY2023Mar 31, 2023-$95.18M–
Q4 FY2022Dec 31, 2022-$66.16M–
Q3 FY2022Sep 30, 2022-$71.35M–
Q2 FY2022Jun 30, 2022-$74.23M–
Q1 FY2022Mar 31, 2022-$97.74M–
Q4 FY2021Dec 31, 2021-$84.09M–
Q3 FY2021Sep 30, 2021-$85.18M–
Q2 FY2021Jun 30, 2021-$117.29M–
Q1 FY2021Mar 31, 2021-$120.75M–
Q4 FY2020Dec 31, 2020-$49.40M–
Q3 FY2020Sep 30, 2020-$68.21M–
Q2 FY2020Jun 30, 2020-$67.80M–
Q1 FY2020Mar 31, 2020-$105.36M–
Q4 FY2019Dec 31, 2019-$93.61M–
Q3 FY2019Sep 30, 2019-$85.59M–
Q2 FY2019Jun 30, 2019-$88.15M–
Q1 FY2019Mar 31, 2019-$103.27M–
Q4 FY2018Dec 31, 2018-$74.19M–
Q3 FY2018Sep 30, 2018-$63.84M–
Q2 FY2018Jun 30, 2018-$67.40M–
Q1 FY2018Mar 31, 2018-$99.00M–
Q4 FY2017Dec 31, 2017-$74.45M–
Q3 FY2017Sep 30, 2017-$77.72M–
Q2 FY2017Jun 30, 2017-$58.99M–
Q1 FY2017Mar 31, 2017-$74.07M–
Q4 FY2016Dec 31, 2016-$51.22M–
Q3 FY2016Sep 30, 2016-$49.03M–

More Agios Pharmaceuticals figures

See a number that looks wrong?